Sovateltide is under clinical development by Pharmazz and currently in Phase I for Hypoxic-Ischemic Encephalopathy. According to GlobalData, Phase I drugs for Hypoxic-Ischemic Encephalopathy does not ...
Background: Hypoxic–ischemic encephalopathy following perinatal asphyxia is a leading cause of neonatal death and disability worldwide. Treatment with therapeutic hypothermia reduced adverse outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback